Retraction: Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity

Yueqiang Jiang; Yanling Ma; RuiChao Li; JianHai Sun

doi:10.18632/oncotarget.28325

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Retraction:

Retraction: Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity

PDF | How to cite

Oncotarget. 2022; 13:1322-1322. https://doi.org/10.18632/oncotarget.28325

Metrics: PDF 545 views | ?

Yueqiang Jiang^1,*, Yanling Ma^2,*, RuiChao Li¹ and JianHai Sun²

¹Department of Gerontology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
²Department of Oncology, the Third People’s Hospital, Wuhan, Hubei Province, China
^*Co-first author

Published: December 17, 2022

Copyright: © 2022 Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: During its investigation, Oncotarget requested the original data for this paper from the authors. The authors state: "After investigation, we determined that some original data were lost and we cannot repeat the results, making data interpretation difficult and conclusion unreliable." All authors have therefore agreed to the retraction of this paper from Oncotarget.

Original article: Oncotarget. 2018; 9:11989–11998. DOI: https://doi.org/10.18632/oncotarget.22857

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28325

Publication Alerts

Post-Publication Promotion

Publication Discount

Retraction:

Retraction: Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity